Phaseline

Targets › HMOX1

HMOX1 (Heme oxygenase 1): drug programs, companies and trials

4 programs from 4 companies in 5 trials: 2 Phase 2, 2 Phase 4, 1 Phase 1; Cardiovascular, Infectious disease, Oncology; next expected readout Dec 2026.

[Heme oxygenase 1]: Catalyzes the oxidative cleavage of heme at the alpha-methene bridge carbon, released as carbon monoxide (CO), to generate biliverdin IXalpha, while releasing the central heme iron chelate as ferrous iron. Affords protection against programmed cell death and this cytoprotective effect relies on its ability to catabolize free heme and prevent it from sensitizing cells to undergo apoptosis..;…. (UniProt, P09601)

Open in Phaseline: the race on HMOX1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Tomsk National Research Medical Center of the Russian Academy of SciencesFerinject (ferric carboxymaltose)
Iron replacement therapy - ferric carboxymaltose complex for iron deficiency correction
HMOX1Phase 4Chronic Heart FailureDec 2026
Oregon Health and Science UniversityIron-Dextran Complex Injection [InFed]
Iron replacement therapy for iron-deficiency anemia
HMOX1, FTH1Phase 4Acute Blood Loss Anemia–
Memorial Sloan Kettering Cancer CenterN-Acetylcysteine (N-AC)
Antioxidant; mucolytic agent; precursor to glutathione
HMOX1Phase 2Covid-19; LymphomaMay 2027
Aditya S. Pandey, MDDeferoxamine
Iron chelator that binds free iron and prevents free radical formation
HMOX1Phase 2Aneurysmal Subarachnoid HemorrhageOct 2027

Conditions

Covid-19 (1) Lymphoma (1) Aneurysmal Subarachnoid Hemorrhage (1) Acute Blood Loss Anemia (1) Chronic Heart Failure (1)

Modalities

small molecule (4)

Companies

Memorial Sloan Kettering Cancer Center (1) Aditya S. Pandey, MD (1) Oregon Health and Science University (1) Tomsk National Research Medical Center of the Russian Academy of Sciences (1)

Related targets

FTH1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.